Head-to-head evidence
TE-8105 vs XW003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
TE-8105
Developed by Immunwork
NCT06471530 · Phase 1/2 · completed
This was an open-label, non-randomized, dose-escalation study with no placebo or control group, so it cannot show whether any effect is attributable to the drug itself. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
XW003
Developed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This randomized, triple-blind, placebo-controlled Phase 3 trial (n=664) in adults with overweight or obesity found that ecnoglutide (XW003) produced significantly greater weight loss than placebo at 40 weeks across all three doses tested, up to 13.2% versus about 0.1% with placebo (p<0.0001 for every dose).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07073417 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: TE-8105's landscape · XW003's landscape